Evidence map›Paper›PMID 40109453›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Nafamostat Mesylate Alleviates Renal Ischemia-Reperfusion Injury in a Rat Model Through HMGB1 Modulation: An Omics Analysis -Based Study of the Protective Effect and the Mechanisms Involved].

Yuxuan Wu, Hongqian Li, Linfeng Liu, Yu Wang, Bo Chen, Jiang Liu, Jianhua Qin, Santao Ou, Weihua Wu

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuxuan Wu// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Hongqian Li// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Linfeng Liu// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Yu Wang// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Bo Chen// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Jiang Liu// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Jianhua Qin// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Santao Ou// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Weihua Wu// （ 646000） Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Provincical Clinical Research Center for Nephrology/Key Laboratory of Metabolic Diseases, Luzhou 646000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the organ protective role and the underlying mechanism of nafamostat mesylate (NM) in a renal ischemia-reperfusion injury (RIRI) model. Methods: A total of 21 healthy male Sprague-Dawley (SD) rats were randomly assigned to 3 groups ( Results: 1) Compared with those of the Sham group, the levels of cystatin C, creatinine, and inflammatory factors in the RIRI and NM groups were significantly increased, and the expression levels in the NM group were lower than those in the RIRI group ( Conclusion: NM may play a protective role in a rat model of RIRI, and its underlying mechanisms may be related to the regulation of the functional abnormalities of HMGB1-mediated macrophages.

Indexed as

GuanidinesHMGB1 ProteinKidneyReperfusion InjuryAnimalsApoptosisBenzamidinesCreatinineCystatin CDisease Models, AnimalMaleRatsRats, Sprague-DawleyBenzamidinesCreatinineCystatin CGuanidinesHbp1 protein, ratHMGB1 ProteinnafamostatAcute kidney injuryHigh-mobility group protein B1Ischemia-reperfusionMonocyte-macrophageNafamostat mesylate

Identifiers

PMID40109453
PMCPMC11913999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.